Sandoz Canada launches two new generic therapies for hypertension
Published: Mar 07, 2018
BOUCHERVILLE, QC, March 7, 2018 /CNW/ - Sandoz Canada announced today that it has launched two new generic alternatives to therapies that have been available under the brand names Coversyl and Coversyl Plus for the treatment of hypertension.
"We are very pleased to be bringing cost-effective generic alternatives to these important medicines to Canadians across the country," said Michel Robidoux, President and General Manager of Sandoz Canada. "Sandoz® Perindopril Erbumine and Sandoz® Perindopril Erbumine/Indapamide will help to make high-quality treatment more accessible to Canadians and could save the health care system millions of dollars every year through prescription of high-quality, cost-effective generics."
Sandoz® Perindopril Erbumine is an angiotensin converting enzyme (ACE) inhibitor used to treat adults with mild to moderate essential hypertension and congestive heart failure. Concentrations include 2 mg, 4 mg, and 8 mg tablets.
Sandoz Canada is also launching Sandoz® Perindopril Erbumine/Indapamide. The feature of the combo is that it includes diuretics, which help control blood pressure by getting rid of excess salt and water. Concentrations include 2 mg / 0.625 mg, 4 mg / 1.25 mg and 8 mg / 2.5 mg tablets.
According to Hypertension Canada, 7.5 million people in Canada live with hypertension, which is among the top risk factors for death, disability and reduced lifespan. Over 90% of Canadians are estimated to develop hypertension if they live an average life span. If untreated, hypertension poses increased risk of heart failure, heart attack, kidney failure or stroke1.
® Registered trademark owned or used under license by their respective registrants.
1) UpToDate, Patient education: High blood pressure treatment in adults (Beyond the Basics), August 2017